Tenofovir (disoproxil or alafenamide)
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Tenofovir (disoproxil or alafenamide) and local guidelines before prescribing.
Mechanism
Nucleotide reverse transcriptase inhibitor.
Uses
HIV infection, chronic hepatitis B, HIV pre-exposure prophylaxis.
Dosing
- Tenofovir (disoproxil 245 mg or alafenamide 25 mg daily) or entecavir (0.5 mg daily) - usually lifelong; cure is rare.
Gastroenterology: Liver disease
Side effects
Renal tubular dysfunction, reduced bone density, nausea, hepatitis flare on stopping (hepatitis B).
Interactions
NSAIDs and nephrotoxic drugs; didanosine.
Contraindications and cautions
Renal impairment (disoproxil)
Monitoring
eGFR, phosphate, urine protein, HBV DNA
Pregnancy and breastfeeding
Used in pregnancy where indicated
Renal and hepatic impairment
Reduce dose in renal impairment
Overdose and reversal
Supportive
Special advice
Check eGFR, phosphate and urinalysis; do not stop abruptly in hepatitis B.
More from the textbook: uses, cautions and other points
- Fanconi syndrome: Proximal tubule dysfunction causing loss of phosphate, glucose, amino acids and bicarbonate. Causes include myeloma, tenofovir and cystinosis.
Endocrinology: Bone Medicine - Hepatitis B - tenofovir or entecavir (suppress, rarely cure); monitor kidney function and bone with tenofovir disoproxil.
Gastroenterology: Anatomy Physiology Pharmacology - Reactivation: Before chemotherapy, rituximab or other strong immunosuppression, test HBsAg and anti-HBc. Give antiviral prophylaxis (entecavir or tenofovir) if positive - reactivation can cause fatal hepatitis.
Gastroenterology: Liver disease - Tenofovir / entecavir | Chronic hepatitis B; usually long-term; prophylaxis before rituximab or chemotherapy in HBsAg or anti-HBc positive people.
Gastroenterology: Liver disease - Antiviral prophylaxis (entecavir or tenofovir) during and for at least 12–18 months after treatment.
Gastroenterology: Liver disease - Chronic kidney damage | Lithium (nephrogenic DI, chronic interstitial nephritis - monitor eGFR), calcineurin inhibitors , long-term NSAIDs (analgesic nephropathy, papillary necrosis), tenofovir disoproxil (Fanconi syndrome)
Renal: Anatomy, Physiology and Pharmacology - Tenofovir in the third trimester for high viral load.
Gastroenterology: Liver disease - Proximal tubule | Reabsorbs about 65% of sodium and water , all glucose (SGLT2), amino acids, most bicarbonate (carbonic anhydrase), phosphate, urate; secretes drugs (penicillins, methotrexate, furosemide reaches its target this way) | SGLT2 inhibitors , acetazolamide | Fanconi syndrome (glucose, amino acids, phosphate, bicarbonate lost …
Renal: Anatomy, Physiology and Pharmacology
Where it is discussed in the book
- Endocrinology: Bone Medicine (1 mention)
- Gastroenterology: Anatomy Physiology Pharmacology (1 mention)
- Gastroenterology: Liver disease (5 mentions)
- Renal: Anatomy, Physiology and Pharmacology (3 mentions)
- Renal: Tubular Inherited Stones (3 mentions)
- Renal: Glomerular Disease (1 mention)
- Haematology: Myeloma and Lymphoma (1 mention)
- Obstetrics: Medical Problems (1 mention)
- Gynaecology: Sexual health (2 mentions)
- ID: HIV, viral hepatitis and blood-borne viruses (11 mentions)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (1 mention)
- Microbiology: Virology - structure, replication and important viral infections (5 mentions)